Unique vascular protective properties of natural products: Supplements or future main-line drugs with significant anti-atherosclerotic potential?

Vascular Cell

Volumn 4, Issue , 2012, Pages

  Slevin, Mark ^a,b   Ahmed, Nessar ^b   Wang, Qiuyu ^b   McDowell, Garry ^c   Badimon, Lina ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^c EDGE HILL UNIVERSITY   (United Kingdom)

Author keywords

Atherosclerotic plaque; Cardiovascular disease; Natural health products; Vascular protection

Indexed keywords

ACETYLSALICYLIC ACID; AGED GARLIC EXTRACT; CLOPIDOGREL; GARLIC EXTRACT; GREEN TEA EXTRACT; PRASUGREL; RESVERATROL; ROSUVASTATIN; TICAGRELOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CAROTID ATHEROSCLEROSIS; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEART PROTECTION; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VASCULARIZATION;

ALLIUM SATIVUM;

EID: 84864990987     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-4-9     Document Type: Review

References (68)

1. Risk factors for the development of atherosclerosis in childhood and adolescence. Santos MG, Pegoraro M, Sandrini F, et al. Arq Bras Cardiol 2008 90 276 283 18516390
2. Inflammation, endothelial cell activation and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. Marroquin OC, Kip KE, Mulukutla SR, et al. Am Heart J 2005 150 109 115 10.1016/j.ahj.2004.08.003 16084156 (Pubitemid 41097436)
3. A definition of initial fatty streak and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis. Stary HC, Chandler AB, Glagov S, et al. Circulation 1994 89 2462 2478 10.1161/01.CIR.89.5.2462 8181179 (Pubitemid 24142837)
4. From endothelial dysfunction to atherosclerosis. Sitia S, Tomasoni L, Atzeni F, et al. Autoimmun Rev 2010 9 830 834 10.1016/j.autrev.2010.07.016 20678595
5. Endothelial dysfunction: potential clinical applications. Tousoulis D, Koutsogiannis M, Papageorgiou N, et al. Minerva Med 2010 101 271 284 21030938
6. Identification of a 'snapshot' of co-expressed angiogenic markers in laser-dissected vessels from unstable carotid plaques with targeted arrays. Slevin M, Turu MM, Rovira N, et al. J Vasc Res 2010 47 323 335 10.1159/000265566 20016206
7. Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention. Slevin M, Krupinski J, Badimon L, J Angiogenesis Res 2009 21 1 4
8. The vicious circle between oxidative stress and inflammation in atherosclerosis. Hulsmans M, Holvoet P, J Cell Mol Med 2010 14 70 78 10.1111/j.1582-4934.2009.00978.x 19968738
9. NAD(P)H oxidases in coronary artery disease. Arora S, Vaishya R, Dabla PK, et al. Adv Clin Chem 2010 50 65 86 20521441
10. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Holvoet P, Verh K Acad Geneeskd Belg 2008 70 193 219 18669160
11. The role of AGEs in cardiovasculr disease. Jandeleit-Dahm K, Cooper ME, Curr Pharm Des 2008 14 979 986 10.2174/138161208784139684 18473849 (Pubitemid 351753286)
12. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Hochtl T, Tentzeris I, Schror K, et al. Fundam Clin Pharmacol 2011 [Epub ahead of print]
13. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Toyama K, Sugiyama S, Oka H, et al. Atherosclerosis 2011 217 158 164 10.1016/j.atherosclerosis.2011.02.050 21458815
14. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Takayama T, Hiro T, Yamagishi M, et al. Circ J 2009 73 2110 2117 10.1253/circj.CJ-09-0358 19801853
15. The influence of rosuvastatin and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients. Semenova AE, Sergienko IV, Masenko VP, et al. Acta Cardiol 2009 64 405 409 10.2143/AC.64.3.2038029 19593954
16. Rate control with ivabradine: angina pectoris and beyond. Parakh N, Bhargava B, Am J Cardiovasc Drugs 2011 11 1 12 10.2165/11584840-000000000-00000 21090826
17. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Ferrari R, Guardigli G, Ceconi C, Cardiovasc Drugs Ther 2010 24 331 339 10.1007/s10557-010-6244-x 20577898
18. Patients with acute coronary syndrome and nonobstructive coronary artery disease in the real world are markedly undertreated. De Ferrari GM, Leonardi S, Baduena L, J Cardiovasc Med 2011 12 700 708 10.2459/JCM.0b013e328348e575
19. Coronary heart disease prevention: nutrients, foods, and dietry patterns. Bhupathiraju SN, Tucker KL, Clin Chim Acta 2011 412 1493 1514 10.1016/j.cca.2011.04.038 21575619
20. Cardiovascular friendly natural products: a promising approach in the management of CVD. Shukla SK, Gupta S, Ojha SK, Nat Prod Res 2010 24 873 898 10.1080/14786410903417378 20461632
21. The prevalence of natural health product use in patients with acute cardiovascular disease. Alherbish A, Charrois TL, Ackman ML, et al. PLoS One 2011 6 19623 10.1371/journal.pone.0019623
22. The effects of dietry and nutrient interventions on arterial stiffness: a systematic review. Pase MP, Grima NA, Sarris J, Am J Clin Nutr 2011 93 446 454 10.3945/ajcn.110.002725 21147858
23. Aged garlic extract scavanges superoxide radicals. Morihara N, Hayama M, Fujii H, Plant Foods Hum Nutr 2011 66 17 21 10.1007/s11130-011-0216-6 21318303
24. Garlic reduces dementia and heart-disease risk. Borek C, J Nutr 2006 136 810 812
25. Aged garlic extract inhibits homocysteine-induced scavenger receptor CD36 expression and oxidized low-density lipoprotein cholesterol uptake in human macrophages in vitro. Morihara N, Ide N, Weiss N, J Ethnopharmacol 2011 134 711 716 10.1016/j.jep.2011.01.021 21256950
26. 5-hydroxymethylfurfural from black garlic extract prevents TNFα-induced monocyte cell adhesion to HUVECs by suppression of vascular cell adhesion molecule-1 expression, reactive oxygen species generation and NF-κB activation. Kim HK, Choi YW, Lee EN, et al. Phytother Res 2011 [Epub ahead of print]
27. Chloroform extract of aged black garlic attenuates TNF-α-induced ROS generation, VCAM expression, NF-κB activation and adhesiveness for monocytes in human umbilical vein endothelial cells. Lee EN, Choi YW, Kim HK, et al. Phytother Res 2011 25 92 100 10.1002/ptr.3230 20623600
28. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Berginc K, Zakelj S, Kristi A, Eur J Nutr 2010 49 373 384 10.1007/s00394-010-0095-x 20140680
29. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomised clinical trial. Budoff MJ, Ahmadi N, Gul KM, et al. Prev Med 2009 49 101 107 10.1016/j.ypmed.2009.06.018 19573556
30. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Ried K, Frank OR, Stocks NP, Maturitas 2010 67 144 150 10.1016/j.maturitas.2010.06.001 20594781
31. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. Ahmad MS, Ahmed N, J Nutr 2006 136 796 799
32. RAGE biology, atherosclerosis and diabetes. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA, Clin Sci 2011 121 43 55 10.1042/CS20100501 21457145
33. RAGE and cardiovascular disease. Park S, Yoon SJ, Tae HJ, et al. Front Biosci 2011 16 486 497 10.2741/3700 21196183
34. The antioxidant N-Acetylcysteine promotes atherosclerotic plaque stabilization through suppression of RAGE, MMPs and NF-κB in ApoE-deficient mice. Lu Y, Qin W, Shen T, et al. J Atheroscler Thromb 2011 [Epub ahead of print]
35. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Csiszar A, Ann N Y Acad Sci 2011 1215 117 122 10.1111/j.1749-6632.2010.05848.x 21261649
36. Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox" Lippi G, Franchini M, Favaloro, et al. Semin Thromb Hemost 2010 36 59 70 10.1055/s-0030-1248725 20391297
37. Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells. Balestrieri ML, Schiano C, Felice, et al. J Biochem 2008 143 179 186 17984121 (Pubitemid 351249832)
38. Roles of SIRT! In high glucose-induced endothelial impairment: association with diabetic atherosclerosis. Yang J, Wang N, Zhu Y, et al. Arch Med Res 2011 [Epub ahead of print]
39. Mechanisms of resveratrol-induced platelet apoptosis. Lin KH, Hsiao G, Shih CM, et al. Cardiovasc Res 2009 83 575 585 10.1093/cvr/cvp139 19423619
40. Resveratrol inhibits monocyte cell chemotaxix to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinase-dependent mechanism. Cicha I, Regler M, Urschel K, et al. J Atheroscler Thromb 2011 [Epub ahead of print]
41. Role of Akt-dependent pathway in resveratrol-mediated cardioprotection after trauma-hemorrhage. Tsai YF, Liu FC, Lau YT, et al. J Surg Res 2011 [Epub ahead of print]
42. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles in NF-kappaB and MAPK. Kang OH, Jang HJ, Chae HS, et al. Pharmacol Res 2009 59 330 337 10.1016/j.phrs.2009.01.009 19416633
43. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Norata GD, Marchesi P, Passamonti S, et al. Atherosclerosis 2007 191 265 271 10.1016/j. atherosclerosis.2006.05.047 16806235 (Pubitemid 46400710)
44. Inhibition of neointimal formation by trans-resveratrol: role of phosphatidyl inositol 3-kinase-dependent Nrf2 activation in heme oxygenase-1 induction. Kim JW, Lim SC, Lee MY, et al. Mol Nutr Food Res 2010 54 1497 1505 10.1002/mnfr.201000016 20486211
45. Resveratrol inhibits mTOR mitogenic signalling evoked by oxidized LDL in smooth muscle cells. Brito PM, Devillard R, Negre-Salvayre A, et al. Atherosclerosis 2009 205 126 134 10.1016/j.atherosclerosis.2008.11.011 19108833
46. Repeated and long-term treatment with physiologic concentrations of resveratrol promotes NO production in vascular endothelial cells. Takahashi S, Nakashima Y, Br J Nutr 2011 [Epub ahead of print]
47. Resveratrol up-regulates SIRT-1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. Yun JM, Chien A, Jialal I, et al. J Nutr Biochem 2011 [Epub ahead of print]
48. Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats. Arrick DM, Sun H, Patel KP, et al. Am J Physiol Heart Circ Physiol 2011 301 696 703 10.1152/ajpheart.00312.2011
49. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Gkaliagakousi E, Ferro A, Front Biosci 2011 16 1873 1897 10.2741/3828 21196271
50. Multifaceted approach to resveratrol bioactivity: focus on anti-oxidant action, cell signalling and safety. Kovacic P, Somanathan R, Oxid Med Cell Longev 2010 3 86 100 10.4161/oxim.3.2.11147 20716933
51. Reduction of blood cholesterol and ischaemic injury in the hypercholesteromic rabbits with modified resveratrol, longevinex [corrected]. Juhasz B, Das DK, Kertesz A, et al. Mol Cell Biochem 2011 348 199 203 10.1007/s11010-010-0615-2 21052791
52. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischaemia. Robich MP, Osipov RM, Chu LM, et al. Eur J Pharmacol 2011 664 45 53 10.1016/j.ejphar.2011.04.059 21575630
53. Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Chen CJ, Yu W, Fu YC, et al. Biochem Biophys Res Commun 2009 378 389 393 10.1016/j.bbrc.2008.11.110 19059213
54. Beneficial effects of green tea: a literature review. Chacko SM, Thambi PT, Kuttan R, et al. Indian J Gastroenterol 2010 30 118 127
55. Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hyperchlorous acid, atherosclerotic factors, and pro-inflammatory cytokines. Hsu SP, Wu MS, Yang CC, et al. Am J Clin Nutr 2007 86 1539 1547 17991670
56. Tea flavonoids and cardiovascular health. Hodgson JM, Croft KD, Mol Aspects Med 2010 31 495 502 10.1016/j.mam.2010.09.004 20837049
57. The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. Kuriyama S, J Nutr 2008 138 1548 1553
58. Tea consumption enhances endothelial-dependent vasodilation: a meta-analysis. Ras RT, Zock PL, Draijer R, PLoS One 2011 6 16974 10.1371/journal.pone.0016974
59. Green tea reduces oxidability and improves vascular function. Tinahones FJ, Rubio MA, Garrido-Sanchez L, et al. J Am Col Nutr 2008 27 209 213
60. Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. Sabu MC, Smitha K, Kuttan R, J Ethnopharmacol 2002 83 109 116 10.1016/S0378-8741(02)00217-9 12413715 (Pubitemid 36164734)
61. Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. Kobayashi Y, Suzuki M, Satsua H, J Agric Food Chem 2000 48 5618 5623 10.1021/jf0006832 11087528
62. Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells. Liu J, Ying C, Meng Y, et al. Blood Coagul Fibrinolysis 2009 20 552 557 10.1097/MBC.0b013e32832e05f0 19713834
63. Green tea extract decreases oxidative stress and improves insulin sensitivity in an animal model of insulin resistance, the fructose fed rat. Hininger-Favier I, Benaraba R, Coves S, et al. J Am Coll Nutr 2009 28 355 361 20368373
64. Effect of resveratrol on fat mobilization. Baile CA, Yang YJ, Rayalam S, et al. Ann NY Acad Sci 2011 1215 40 47 10.1111/j.1749-6632.2010.05845.x 21261640
65. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. Hollman PC, Cassidy A, Comte B, et al. J Nutr 2011 141 989 1009 10.3945/jn.110.131490
66. Challenges of translating basic research into therapeutics: resveratrol as an example. Smoliga JM, Vanf O, Baur JA, J Gerentol A Biol Sci Med Sci 2011 [Epub ahead of print]
67. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Schmidt M, Schmitz HJ, Baumgart A, et al. Food Chem Toxicol 2005 43 307 314 10.1016/j.fct.2004.11.001 15621343 (Pubitemid 40037949)
68. Effects of (-)-epigallocatechin-3-gallate on pancreatic beta-cell damage in streptozotocin-induced diabetic rats. Yun SY, Kim SP, Song DK, Eur J Pharmacol 2006 541 115 121 10.1016/j.ejphar.2006.04.040 16765345 (Pubitemid 43903469)